Cardiovascular disorder therapy - SalubrisBio
Latest Information Update: 06 Oct 2020
At a glance
- Originator SalubrisBio
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 29 Sep 2020 Cardiovascular disorder therapy is available for licensing as of 29 Sep 2020 (http://salubrisbio.com/Portal/Partner.aspx)
- 24 Sep 2020 Preclinical trials in Cardiovascular disorders in USA (unspecified route) (SalubrisBio pipeline, September 2020)